PMID- 20179227
OWN - NLM
STAT- MEDLINE
DCOM- 20100520
LR  - 20220409
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 16
IP  - 5
DP  - 2010 Mar 1
TI  - Everolimus.
PG  - 1368-72
LID - 10.1158/1078-0432.CCR-09-1314 [doi]
AB  - Everolimus, an orally administered rapamycin analog, has recently been approved 
      by the U.S. Food and Drug Administration for treatment of renal cell carcinoma 
      (RCC) refractory to inhibitors of vascular endothelial growth factor (VEGF) 
      receptor signaling. Everolimus significantly increased progression-free survival 
      (median PFS for the everolimus treated group was 4.0 months versus 1.9 months for 
      the placebo group), although tumor regressions were observed only infrequently. 
      Although the target for everolimus, [the serine-threonine kinase mammalian target 
      of rapamycin (mTOR)] is well established, the mechanism by which this agent 
      retards tumor growth is not well defined. Further, biomarkers that predict tumor 
      sensitivity are still elusive. The mechanism of action, preclinical antitumor 
      activity, and clinical activity of everolimus against RCC are reviewed.
FAU - Houghton, Peter J
AU  - Houghton PJ
AD  - Center for Childhood Cancer, The Research Institute, Nationwide Children's 
      Hospital, Columbus, Ohio 43205, USA. Peter.Houghton@nationwidechildrens.org
LA  - eng
GR  - R01 CA077776/CA/NCI NIH HHS/United States
GR  - CA23099/CA/NCI NIH HHS/United States
GR  - N01 CM042216/CM/NCI NIH HHS/United States
GR  - P01 CA023099/CA/NCI NIH HHS/United States
GR  - P01 CA023099-310011/CA/NCI NIH HHS/United States
GR  - CA77776/CA/NCI NIH HHS/United States
GR  - R01 CA077776-11/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20100223
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Clinical Trials as Topic
MH  - Everolimus
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy
MH  - Sirolimus/*analogs & derivatives/pharmacology
PMC - PMC3003868
MID - NIHMS167833
EDAT- 2010/02/25 06:00
MHDA- 2010/05/21 06:00
PMCR- 2011/03/01
CRDT- 2010/02/25 06:00
PHST- 2010/02/25 06:00 [entrez]
PHST- 2010/02/25 06:00 [pubmed]
PHST- 2010/05/21 06:00 [medline]
PHST- 2011/03/01 00:00 [pmc-release]
AID - 1078-0432.CCR-09-1314 [pii]
AID - 10.1158/1078-0432.CCR-09-1314 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2010 Mar 1;16(5):1368-72. doi: 10.1158/1078-0432.CCR-09-1314. 
      Epub 2010 Feb 23.